Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2018
Price : $35 *
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 13 Feb 2014 New trial record
- 24 Dec 2012 Status changed from recruiting to active, not recruiting, as reported by ClinicalTrials.gov.